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OBJECTIVES: Partial breast irradiation (PBI) can be considered a safe alternative to
standard whole breast irradiation (WBI) in favourable early breast cancer and,
profitably, is delivered in a shorter time. Four different techniques have been de-
scribed in randomized trials (follow-up  4 years): intraoperative-radiotherapy
(IORT), delivered at the time of tumorectomy; low-dose-rate brachytherapy (LDR),
delivered in 3 days; external-beam radiotherapy (EBRT) and high-dose-rate brachy-
therapy (HDR), both delivered in 5 days. For comparison, WBI is delivered in seven
weeks. The objective of this study was to compare the cost-effectiveness of the 4
different technical approaches to PBI, for the treatment of selected favourable early
stage breast cancer patients, using current cost estimations within the Spanish
Public Health System. METHODS: A decision-analysis model was performed using
efficacy data from previous prospective trials, calculated in years without mastec-
tomy (YWM). Direct costs were estimated based on charges applied by Madrid’s
Autonomous Community, and were expressed in Euros (€). For each modality of
PBI, local recurrence rates where individualized, and charges weighted for the
frequency of its occurrence. A probabilistic sensitivity analysis was conducted to
evaluate the robustness of the results. RESULTS: A total cost of 5488.25 € was
estimated for EBRT, 6595.87 € for LDR, 7454.10 € for HDR, and 8895,71 € for IORT. The
incremental cost-effectiveness ratio (ICER) comparing IORT to EBRT was 17209.41
€/YWM. All brachytherapy techniques (LDR and HDR) were dominated. Sensitivity
analysis showed that ICER depends mainly on recurrence level after EBRT, but also
on IORT costs. CONCLUSIONS: In a Spanish Public Health Care scenario, IORT
shows a reasonable a cost-effectiveness ratio for patients with early stage breast
cancer and, due to its intrasurgical administration (same hospital admission re-
quired for surgery), should be considered a compelling alternative, in particular for
patients with complex transportation demands to access radiotherapy facilities.
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OBJECTIVES: In breast cancer, adjuvant chemotherapy is often prescribed as a
precautionary measure and sometimes unnecessarily. A diagnostic test based on
an analysis of 21 genes estimating the risk of recurrence at 10 years for women with
breast cancer in early stage has been developed (Oncotype-DX®). A cost-effective-
ness model was implemented to evaluate the long-term costs and clinical out-
comes associated with introducing this test to inform decision on adjuvant che-
motherapy in France. METHODS: A Markov model was implemented to evaluate
the impact of the test in terms of costs, life-years gained and quality-adjusted
life-years (QALYs) in French clinical practice for patients with ER , HER2-, node-
negative early-stage breast cancer, over 30 years. A strategy using the genetic test
to decide whether to administer chemotherapy or not was compared to utilization
of standard decision criteria. The model accounted for the costs of testing, adjuvant
chemotherapy and recurrence. Utilities were dependent on recurrence status and
undergoing chemotherapy. Input data were obtained from a study evaluating the
proportions of patients in which the genetic test led to change the oncologist’s
decision, as well as scientific literature and grey literature. RESULTS: The test was
associated with savings of €570 (€1600 with productivity loss cost) per patient from
societal perspective and gains of 0.15 life-years and 0.14 QALYs per patient. One-
way sensitivity analyses showed that the cost was most sensitive to the recurrence
cost and QALYs to discount rate and to the proportion of patients for whom the
decision not to give chemotherapy was reversed with the test. CONCLUSIONS: The
use of the test seems to represent efficient use of health care resources in French
practice. This test provides an opportunity to optimize treatment prescription by
avoiding unnecessary chemotherapies and by prescribing chemotherapy to
women who have not received it based on standard decision criteria.
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OBJECTIVES: The EOS 2D/3D X-ray imaging system is a novel technology with
potential clinical benefits in the evaluation of orthopaedic conditions. However,
there is no evidence on other benefits in addition to those derived from reductions
in the radiation dose. This study aims to evaluate the cost-effectiveness of EOS
compared with standard X-ray and highlight some of the typical challenges in the
evaluation of diagnostics.METHODS:A model was developed to evaluate the long-
term cost-effectiveness of EOS. Costs were from a health service perspective and
outcomes were measured as quality-adjusted life years (QALYs). Threshold analy-
sis was used to establish the necessary size of the additional health benefits and
the level of patient throughput needed for EOS to be considered cost-effective.
RESULTS: The incremental cost-effectiveness ratio (ICER) of EOS was well above
thresholds of £20,000 and £30,000 per additional QALY in all orthopaedic conditions
under base-case assumptions. Patient throughput was a major determinant of
cost-effectiveness. Threshold analysis on patient throughput showed that 17,700
to 27,600 scans per year with EOS, compared with 7,530 scans per year with com-
puted radiography (CR), were needed to achieve an ICER of £20,000 per QALY.
Health benefits over and above lower radiation would need to increase consider-
ably for EOS to be considered cost-effective. CONCLUSIONS: The health benefits
estimated from EOS as a result of radiation dose reductions were insufficient to
justify the cost of the system. EOS can only be shown to be cost-effective when
compared to CR if the utilisation of EOS is assumed to be about twice the utilisation
of CR. EOS highlights some of the difficulties of establishing the relevant care
pathway, potential indications, patient benefit from the imaging features, and pa-
tient throughput. The evaluation of EOS is an example of how methodological
challenges presented by diagnostics can be overcome.
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OBJECTIVES: Evidence from recent clinical studies has shown the benefits of SMBG
plus a structured testing program (SMBGSTG) in non-insulin treated patients
with T2DM. The Structured Testing Protocol (STeP) study found SMBGSTG can
lead to improvements in glycemic control. This study assessed the cost-effective-
ness of SMBGSTG versus SMBG alone from the Spanish health care system per-
spective in the context of recent studies of SMBG that have employed active edu-
cation programs. METHODS: A discrete event simulation model was developed to
simulate the economic and health outcomes based on A1c changes related to using
SMBGSTG or SMBG alone. Baseline A1c (8.4%) changes over 1 year (-1.2% and
-0.9% for SMBGSTG versus SMBG alone), discontinuation and hypoglycemia rates
were from the STeP study. Population and cost inputs were from published Spanish
sources. Over a lifetime horizon (30yrs), the model predicts: diabetes related com-
plications (cardiovascular disease, stroke, amputations, end stage renal disease),
hypoglycemia, life years (LYs) and quality adjusted life years (QALYs). Costs asso-
ciated with events were estimated. Benefits and costs were discounted at 5%. Un-
certainty in model estimates, such as changes in price per strip, treatment groups,
program component, and A1c differences, was explored with sensitivity analyses.
RESULTS: SMBGSTG was predicted to reduce complications and associated costs.
Lowering A1c and consequent complications prevention with SMBGSTG trans-
lated into a dominant incremental cost-effectiveness ratio. Comparisons with a
group not utilizing SMBG yielded similar results. CONCLUSIONS: In the long term,
SMBGSTG is a cost-effective option compared to SMBG alone. An A1c reduction of
0.3% is a cost-effective outcome. Decison makers should consider designing pro-
grams to educate patients about SMBGSTG.
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OBJECTIVES: To assess the cost-effectiveness of TAVI compared with standard
therapy consisting mainly of balloon aortic valvuloplasty (BAV) in patients with
severe aortic stenosis who are ineligible for conventional aortic valve replacement
(AVR) from the perspective of the Ontario health care payer. METHODS: A micro-
simulation decision analytical model was developed to estimate the incremental
costs and benefits associated with both interventions over a lifetime time horizon.
Monthly adverse event and patient mortality rates were determined using data
from the PARTNER randomized control trial (cohort B). Quality of life values were
determined through literature review, expert opinion, and data provided by the
PARTNER investigators. The London Health Sciences Centre Case Costing Initiative
and the Canadian Institute for Health Administration (CIHI) were used to estimate
costs. Extensive sensitivity analyses were performed to explore the impact of un-
certainty surrounding model parameters on the resultant cost-effectiveness esti-
mates. The primary outcome measure was the incremental cost-effectiveness ra-
tio (ICER) with benefits expressed as quality-adjusted life years (QALYs). Costs were
expressed in 2011 CAD$. Both costs and benefits were discounted at 5%. RESULTS:
The base case ICER was approximately $38,448 per QALY gained. The results of the
sensitivity analyses yielded ICERs ranging from approximately $32,238/QALY to
$43,887/QALY. ICER estimates were most sensitive to changes in the cost of the
Edwards SapienTMDevice. CONCLUSIONS: At cost-effectiveness thresholds nor-
mally used to define value for money in health care, TAVI represents a cost-effec-
tive treatment option for patients with severe aortic stenosis who are currently
ineligible to undergo conventional aortic valve replacement in the province of
Ontario.
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OBJECTIVES: Sacral Nerve Modulation (SNM) is a minimally-invasive technology
indicated for overactive bladder (OAB). SNM efficacy has been widely demonstrated
yet its cost-effectiveness in the UK is unknown. The cost-effectiveness of SNM in
patients with refractory idiopathic OAB with urinary incontinence (OAB-wet) was
compared to optimal medical therapy (OMT), Botulinum Toxin A (BoNT-A) and
PTNS from the UK NHS perspective.METHODS:A published Spanish Markov model
was adapted to current UK practice based on existing data and clinical expert
advice. Treatment success was defined as 50% improvement in OAB-wet symp-
toms. Health care resource use included pre-,peri-, and post-procedure; drugs;
follow-ups and adverse events. Both SNM using testing with tined-lead (SNM-
tined-lead) and PNE (SNM-PNE) were evaluated. Incremental-cost-effectiveness-
ratios (ICER;costs per quality-adjusted-life-year)were calculated for SNM vs. OMT
and vs. BoNT-A (10yrs), and SNM vs, PTNS (5yrs); with uni-variate sensitivity
analyses.RESULTS:At 10 years, the cumulative costs of SNM-tined-lead, SNM-PNE,
BoNT-A and OMT were £22,052, £19,952, £18,477, £11,918, respectively; PTNS 5-year
cumulative costs were £17,915.The QALYs for SNM-tined-lead, SNM-PNE, BoNT-A
and OMT were 6.82, 6.64, 6.35 and 5.45 (10yrs), respectively, and 3.44 for PTNS (5yrs).
ICERs were £7,608 and £7,356 for SNM-tined-lead vs. BoNT-A, and vs OMT (10yrs),
respectively; SNM-tined-lead and SNM-PNE were dominant (less costly and more
effective) compared to PTNS (5 years). SNM- tined-lead was cost-effective vs.SNM-
PNE. ICERs were most sensitive to BoNT-A efficacy and costs, but results were
generally robust. CONCLUSIONS: SNM in patients with OAB-wet provides addi-
tional quality of life improvement with higher initial costs for SNM that are offset
by a reduction in follow-up costs over time. This produces ICERs that are clearly
below the threshold generally considered for cost-effectiveness in the UK. SNM
represents value for money compared to OMT, BoNT-A and PTNS, and may be
considered the preferred treatment option in the UK.
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OBJECTIVES: In patients with one to four brain metastasis, if diameter  4 cm, the
standard treatment is whole brain irradiation (WBI) followed by stereotactic radio-
surgery (SRS). There is growing interest on the delivery of isolated SRS, aiming to
reduce side effects of WBI, despite a higher risk of intra-cerebral recurrences. The
objective of this study was to compare the cost-effectiveness of those two strate-
gies, under Brazilians third-part payers’ perspective. METHODS: A meta-analysis
of summary data, including all phase III prospective trails that compared SRS to
WBISRS, was performed. Data about recurrence management, dependant of on
the lesion size, as well as of previous delivered treatment, were also extracted.
Costs were estimated based on charges accordingly to Brazilian Health Care reim-
bursement rates for the private system (CBHPM). Only directs costs were consid-
ered, and were expressed in Brazilian Reais (BRL). A probabilistic sensitivity anal-
ysis was conducted to evaluate the robustness of the results. The perspective was
that from the Brazilian Third Party payer. RESULTS: Three phase III prospective
trials have been selected, including 467 patients. Once there was no difference in
overall survival, effectiveness was evaluated according to local control. After two
years of follow up, 78% [64.2-87.4%] of the SRS patients and 53% [47-57%] of the
WBISRS patients have recurred. The incremental cost-effectiveness ratio (ICER)
comparing WBISRS to SRS was of 7.489,60 BRL/year without cerebral recurrences.
Sensitivity analysis showed that ICER remains acceptable under a wide range of
assumptions . CONCLUSIONS: Results suggested that WBISRS might be consid-
ered as a cost-effective strategy in patients with up to 4 brain metastases. Once no
detrimental survival effect have been shown, SRS can be cost-savings for Brazilians
third-party payers, but patients need to be aware of the risks involved in not deliv-
ering WBI.
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OBJECTIVES: To assess the cost-effectiveness of 3M™ Coban™2 Layer Compres-
sion System (Coban 2) for the treatment of venous leg ulcers in the Dutch health
care setting. METHODS: The health economic evaluation consists of a cost-effec-
tiveness analysis. A Markov model was developed in order to determine the cost-
effectiveness of Coban 2, which was based on different health states and allowed
transitions between these states. Upon initiation of the compression system Coban
2, the patient is supposed to have an ulcer. Over time, the ulcer may heal, but it may
also recur. The treatment with Coban 2 is compared with traditional treatment
(Short Stretch Bandages (SSB)). The primary perspective of the study is that of the
Dutch insurer in 2012. The actual costs, which are included in the study, are prod-
uct costs and treatment costs. Clinical probabilities on healing and recurrence are
derived from clinical published literature. RESULTS: The use of Coban 2 leads to a
total cost of € 600 compared to € 2,663 for traditional care, which leads to cost saving
of € 2,063 per patient over a period of 1 year. The effectiveness for Coban 2 is 84.5%
time without symptoms; the effectiveness for traditional care is 65.0% time with-
out symptoms, which is leading to a gain of 2.3 months without symptoms over
period of 1 year. CONCLUSIONS: The use of Coban 2 versus traditional treatment is
cost-effective, because it is cost saving in combination with a higher effectiveness.
As a consequence the cost savings by Coban 2 also translates into a positive impact
on total health care budget.
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OBJECTIVES: This study evaluated the cost-effectiveness of three leprosy case de-
tection methods in Northern Nigeria to identify the most cost-effective approach to
new case detection for improved leprosy control in Nigeria. METHODS: A cross-
sectional study was carried out to evaluate the additional benefits of using several
case detection methods in addition to routine practice in two north-eastern states
of Nigeria. Primary and secondary data were collected from routine practice re-
cords and the Nigerian Tuberculosis and Leprosy Control Programme of 2009.
Methods evaluated were Rapid Village Survey (RVS), Household Contact Examina-
tion (HCE) and Traditional Healers incentive method (TH). Effectiveness was mea-
sured as number of new leprosy cases detected and cost-effectiveness was ex-
pressed as cost per case detected. Costs were measured from both providers’ and
patients’ perspectives. Additional costs and effects of each method were estimated
by comparing each method against routine practise and expressed as incremental
cost-effectiveness ratio (ICER). All costs were converted to the US Dollar at the 2010
exchange rate. Univariate sensitivity analysis was used to evaluate uncertainties
around the ICER. RESULTS: The ICER for HCE was $142 per additional case detected
at all contact levels and it was the most cost-effective method. At ICER of $194 per
additional case detected, THs method detected more cases at a lower cost than the
RVS which was not cost-effective at $313 per additional case detected. Sensitivity
analysis showed that varying the proportion of shared costs and subsistent wage
for valuing unpaid time did not significantly change the results. CONCLUSIONS:
Complementing routine practice with household contact examination is the most
cost-effective approach to identify new leprosy cases and we recommend that,
depending on acceptability and feasibility, this intervention is introduced for im-
proved case detection in Northern Nigeria.
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OBJECTIVES: To assess the cost-effectiveness of 3M™ CobanTM2 Layer Compres-
sion System (Coban 2) for the treatment of lymphoedema in the Dutch health care
setting. METHODS: The health economic evaluation consists of a cost-effective-
ness analysis. A decision tree model was developed in order to determine the
cost-effectiveness of Coban 2. The entry point of the model consists of patients
with lymphoedema requiring treatment with compression bandages. The treat-
ment with Coban 2 is compared with traditional treatment (Short Stretch Ban-
dages). The primary perspective of the study is that of the Dutch insurer in 2012.
The actual costs, which are included in the study, are product costs and treatment
costs. RESULTS: The use of Coban 2 leads to a mean total cost of € 528 compared to
€ 630 for traditional care, which leads to a cost saving of € 102 per patient. The
effectiveness for Coban 2 is higher because of a shorter treatment period, which
leads to a reduction of the negative impact on Quality of life by lymphoedema.
CONCLUSIONS: The use of Coban 2 versus traditional treatment is cost saving for
each treatment period with a higher effectiveness, due to shorter treatment dura-
tion and improvement in Quality of Life. As a consequence the use of Coban 2 leads
to a positive impact on the total health care budget.
PMD61
COST-EFFECTIVENESS OF POSITRON EMISSION TOMOGRAPHY IN HEAD AND
NECK SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW
Zaim R1, Redekop WK1, De Bree R2, Van Dongen GAMS2, Hoekstra OS2, Uyl-de Groot CA1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2VU University Medical Center,
Amsterdam, The Netherlands
OBJECTIVES: Functional imaging with positron emission tomography (PET) is a
promising non-invasive modality in the clinical management of squamous cell
carcinoma of the head and neck (SCCHN). Currently, there is limited evidence that
points to the potential cost-effectiveness of PET in this setting. The objective of this
study was to assess the methodological quality of cost-effectiveness analyses
(CEAs) of PET in SCCHN. METHODS: A systematic literature review was performed
focusing on CEAs of PET in SCCHN using MEDLINE, EMBASE, NHS EED and the CEA
Registry. Studies were screened according to a priori eligibility criteria. The meth-
odological quality of the primary clinical studies was examined by QUality Assess-
ment of Diagnostic Accuracy Studies checklist. CEAs were critically appraised us-
ing the Drummond checklist. RESULTS: A total of seven studies met the inclusion
criteria. PET or computed tomography (CT) integrated with PET was assessed in two
indications: detection of recurrent disease and screening for metastasis. In each
indication, PET strategy ranged from likely to be cost-effective (in four studies) to
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